Category: Corona Virus Vaccine

Page 4«..3456..1020..»

COVID-19 Booster Vaccination: SARS-CoV-2 Serological Follow-Up Study in Healthcare Workers – Physician’s Weekly

May 3, 2024

The following is a summary of Follow-up SARS-CoV-2 serological study of a health care worker cohort following COVID-19 booster vaccination, published in the April 2024 issue of Infectious Disease by Hnning et al.

Despite vaccination and prior infection, healthcare workers continue to experience breakthrough Omicron infections, highlighting the need to understand immune protection levels against this variant.

Researchers conducted a retrospective analysis of SARS-CoV-2 antibody levels among healthcare workers in a German COVID-19 hospital after the emergence of the Omicron variant.

They conducted the serological survey in January 2022, following previous surveys in 2020 and the introduction of COVID-19 boosters like BNT162b2, ChAdOx1-S, and mRNA-1273. HCWs willingly contributed blood samples and filled out a detailed questionnaire. The study employed an Immunoglobulin G (IgG) ELISA for SARS-CoV-2 serological analyses. Antibody levels were categorized according to HCW demographics, job roles, COVID-19 vaccination status, and history of SARS-CoV-2 infection. Multivariate linear regression was used to evaluate these relationships.

The results showed that amidst the fourth COVID-19 wave in Germany (January 2022), including the emergence of the Omicron variant, 97.7% of HCWs (1482 out of 1517) tested positive for SARS-CoV-2, contrasting with 4.6% during the second wave in December 2020. About 80% had received three COVID-19 vaccine doses, with 15% reporting previous lab-confirmed SARS-CoV-2 infection. SARS-CoV-2 IgG geometric mean titers ranged from 335 (95% CI: 258434) among those double-vaccinated without previous infection to 2204 (95% CI: 19192531) among those triple-vaccinated with prior infection. Heterologous COVID-19 vaccination regimens, including an mRNA-1273 booster, correlated significantly with the highest IgG antibody levels. Following COVID-19 booster vaccination, 31 HCWs who had reported a SARS-CoV-2 infection (May 2020 and January 2022) experienced an 8 to 10-fold increase in IgG antibody levels.

Investigators concluded that waning immunity from vaccination and prior infection necessitates ongoing booster programs, especially mRNA vaccines, for HCWs facing Omicron variant threats.

Source: bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-024-09338-5

Read more from the original source:

COVID-19 Booster Vaccination: SARS-CoV-2 Serological Follow-Up Study in Healthcare Workers - Physician's Weekly

New study to improve vaccines and therapeutics development – University of Oxford

May 3, 2024

A first-of-its-kind study led by the University of Oxford has successfully investigated human immunity against COVID-19 in people who already have antibodies against it.

The results suggest that previous infection, together with vaccination, offers strong protection against the original COVID-19 strain.

People who do not have antibodies against a particular infectious agent are seronegative and those who have antibodies are called seropositive. Over 99% of the UK population and 59% of the world's population is seropositive, which means they already have antibodies against COVID-19. This means finding seronegative volunteers for an infection model is increasingly very difficult as most people have been either infected, vaccinated, or both.

For vaccine development, researchers create Controlled Human Infection Models (CHIMs), where they deliberately infect healthy volunteers under very carefully controlled clinical conditions. These CHIMs can then be used to rapidly test or compare new vaccines or treatments in a controlled environment. For this study, researchers wanted to use a COVID-19 CHIM to measure what kind of immune responses stop people who have been previously infected and/or vaccinated from being infected again.

The data from this COVCHIM01 study showed durable immunity post-infection/vaccination against the original COVID-19 virus. The study compared the immune responses of volunteers who were infected in this study with those who were uninfected and found that antibodies in the lining of the nose, the route the virus enters the body, may be important in preventing mild infections.

A number of participants who were able to avoid developing infection with the original strain of virus used in the study subsequently developed infections in the community with the Omicron variant. The researchers are investigating this further by pursuing the use of newer variants to create a CHIM with a sufficient rate of infection to enable the assessment of new vaccines or COVID-19 treatments.

Such studies are important to find the most efficient and effective way to test new treatments and vaccines so that they can be utilised as soon as possible.

Professor Helen McShane, Professor of Vaccinology at the Department of Paediatrics, Director of the National Institute for Health and Care Research Oxford Biomedical Research Centre and the lead and corresponding author of the COVCHIM01 study, said: This is a really important proof of concept study demonstrating that controlled human infection studies can be safely carried out during a pandemic and importantly provide valuable information that is difficult to obtain in traditional field studies. We hope this provides confidence in the use of human infection studies as a tool both for the development of improved COVID vaccines and therapeutics and for potential future pandemics.

Published in The Lancet Microbe, this was the first study undertaken at the new NIHR Oxford Clinical Research Facility, Churchill Hospital, Oxford and was funded by the Wellcome Trust, the Department for Health and Social Care/UK Health Security Agency and the NIHR Oxford Biomedical Research Centre.

Link to the paper the Lancet

Originally posted here:

New study to improve vaccines and therapeutics development - University of Oxford

Persistence of COVID-19 Human Milk Antibodies After Maternal COVID-19 Vaccination: Systematic Review and Meta … – Cureus

May 3, 2024

Specialty

Please choose I'm not a medical professional. Allergy and Immunology Anatomy Anesthesiology Cardiac/Thoracic/Vascular Surgery Cardiology Critical Care Dentistry Dermatology Diabetes and Endocrinology Emergency Medicine Epidemiology and Public Health Family Medicine Forensic Medicine Gastroenterology General Practice Genetics Geriatrics Health Policy Hematology HIV/AIDS Hospital-based Medicine I'm not a medical professional. Infectious Disease Integrative/Complementary Medicine Internal Medicine Internal Medicine-Pediatrics Medical Education and Simulation Medical Physics Medical Student Nephrology Neurological Surgery Neurology Nuclear Medicine Nutrition Obstetrics and Gynecology Occupational Health Oncology Ophthalmology Optometry Oral Medicine Orthopaedics Osteopathic Medicine Otolaryngology Pain Management Palliative Care Pathology Pediatrics Pediatric Surgery Physical Medicine and Rehabilitation Plastic Surgery Podiatry Preventive Medicine Psychiatry Psychology Pulmonology Radiation Oncology Radiology Rheumatology Substance Use and Addiction Surgery Therapeutics Trauma Urology Miscellaneous

View post:

Persistence of COVID-19 Human Milk Antibodies After Maternal COVID-19 Vaccination: Systematic Review and Meta ... - Cureus

AstraZeneca, Serum Institute to be sued by parents of woman who died after Covishield jab: What happened? – Firstpost

May 3, 2024

Karunya Venugopal, a 20-year-old, died in July 2021 after getting COVID-19 vaccine. Image Courtesy: X/@gvenugopalan

The bereaved parents of a young woman who died in July 2021 are planning to sue AstraZeneca and the Serum Institute of India (SII). They say their daughter passed away after taking the Covishield jab, manufactured by SII in India.

The development comes after reports surfaced about the British-Swedish pharmaceutical giant AstraZenecas admission in court documents in the United Kingdom that its COVID-19 vaccine, in rare cases, can cause Thrombosis with Thrombocytopenia Syndrome (TTS). AstraZenecas COVID jab was sold as Covishield in India.

Advertisement

TTS is a rare condition that leads to blood clotting and low platelet count.

Lets take a closer look.

What happened?

In July 2021, Karunya Venugopal, a 20-year-old data science student, died a month after getting vaccinated, as per a Scroll report.

After being hospitalised for weeks, she passed away due to multisystem inflammatory syndrome.

She developed severe complications eight days after taking the vaccine and died after a month in spite of three weeks of tertiary care hospitalisation, her father, Venugopalan Govindan, told Economic Times (ET) in late 2022.

She had no pre-existing health conditions and was completely healthy prior to taking the vaccine, he added.

In November 2021, the health ministrys immunisation division, after its inquiry, classified Karunyas death as B1, which meant that the AEFI (adverse event following immunisation) had a temporal relationship with the vaccination, but there was insufficient evidence to prove it was caused by the vaccine.

Govindan approached the Supreme Court, seeking monetary compensation from the government and for creating a protocol for early detection and treatment of AEFIs.

In November 2022, the Centre told the apex court that the government could not be held liable to provide compensation for the deaths due to the administration of COVID-19 vaccines. The government had said it took substantial efforts to ensure a safe and effective COVID-19 vaccination drive, reported The Hindu.

Advertisement

ALSO READ: AstraZeneca vaccines side effects. Why Covishield takers shouldnt worry

Karunyas parents mull suing SII

Now, after AstraZeneca accepted for the first time that its COVID-19 vaccine can cause TTS in rare cases, Karunyas parents are mulling taking SII to court, as per an ET report. Govindan said the pharmaceutical giants admission has come too late after so many lives have been lost.

AstraZeneca and SII should have stopped the manufacture and supply of these vaccines when 15 European countries either suspended or age-limited these due to deaths from blood clots that happened in March 2021, within a couple of months of the rollout of the vaccine itself, he told ET.

Advertisement

Govindan also questioned the government and Covishield maker for not halting the rollout of the vaccine after data about its adverse effects emerged from around the world.

If sufficient remedies arent obtained, for the sake of justice and to prevent recurrence of this atrocity that was perpetrated in the name of public health, we will file fresh cases against any and all of those perpetrators because of whose actions the deaths of our children ensued, he was quoted as saying by ET.

Eight of the victims families have connected and I am echoing the common sentiments of all of us, Govindan said, as per NDTV.

Advertisement

The first reports of a link between AstraZenecas COVID-19 shots and TTS surfaced in early 2021. Several European countries, including Denmark, even stopped the use of the vaccine over these concerns for a while.

Another death after taking Covishield

Rithaika Sri Omtri, 18, got the first dose of Covishield in May 2021 in Hyderabad. As per a Scroll report, within five days of being vaccinated, she experienced a prickling sensation in her fingers and, later, a high fever.

As her fever did not subside for a few days, a doctor suggested her a blood test which revealed her platelets had dropped to a dangerous low of 40,000 per cubic millimetre, compared to a normal range between 1.5 lakh and 4 lakh.

Advertisement

Over 10 days later, Rithaika started vomiting and could not walk. An MRI scan of her brain showed that she had multiple blood clots and a haemorrhage in the right frontal region, Scroll reported.

Despite efforts to save her, she was declared brain dead, two weeks after her vaccination.

As per Scroll, Rithaika had suffered a vaccine-induced (immune) thrombotic thrombocytopenia or VITT, a rare adverse effect that leads to blood clots and low platelet count.

VITT was reported in some people who got adenoviral vector COVID-19 vaccines such as AstraZenecas Vaxzevria (marketed as Covishield in India) and Johnson & Johnsons Janssen shots.

A probe by the AEFI committee categorised Rithaikas death under the A1 cetagory, meaning a vaccine product related reaction, reported ET.

Rithaikas mother, Rachana Gangu, was the second petitioner, who along with Govindan, had moved the apex court in late 2021, alleging her child died due to severe complications after getting the first dose of the COVID-19 vaccine.

In her writ petition, she had demanded compensation and the establishment of an expert medical board to inquire and probe her daughters death.

The cases in UK

AstraZeneca is being sued in a class action in the UK High Court over claims that its COVID-19 vaccine, developed with the University of Oxford, caused death and serious harm in 51 cases.

Victims and grieving relatives are seeking damages estimated to be valued up to 100 million pounds.

The first case against the pharmaceutical giant was filed last year by Jamie Scott, who was left with a permanent brain injury after suffering from a blood clot and a bleed on the brain. This happened after he got the vaccine in April 2021 and Scott has been unable to work since then, The Daily Telegraph reported.

While AstraZeneca is contesting the claims, it has accepted, in a legal document submitted to the High Court in February that its COVID vaccine can, in very rare cases, cause TTS, the report added.

With inputs from agencies

Find us on YouTube

Originally posted here:

AstraZeneca, Serum Institute to be sued by parents of woman who died after Covishield jab: What happened? - Firstpost

Covid-19 Inquiry: Idea to replace Swann during pandemic ‘bizarre’ – BBC.com

May 3, 2024

2 May 2024

Ulster Unionist leader Doug Beattie wants to meet the head of the NI Civil Service to discuss revelations about a "radical" idea to replace Robin Swann during the Covid crisis.

The detail was contained in documents published by the UK Covid Inquiry which is currently sitting in Belfast.

It was suggested that Mr Swann could be moved to give the larger Stormont parties control over the health brief.

Doug Beattie described the idea as "incredibly bizarre".

He also said it called into question the impartiality of the civil service.

The civil servant who floated the idea was Hugh Widdis who at the time was senior legal advisor to the Executive. He is now permanent secretary at the Department of Justice.

The idea - which he recognised was "radical" and may not be "palatable" - was to ask Mr Swann to take on a different ministry during the pandemic to allow a DUP or Sinn Fin politician to take on the key role in health.

The context was an email exchange between civil servants in the early days of the pandemic, at the end of March 2020, when ministers were working out how best to deal with the developing public health crisis.

An email from the then head of the civil service, David Sterling, to fellow officials quoted the then deputy first minister Michelle O'Neill telling him "we need to be driving this crisis, we need to be in control".

Image source, Liam McBurney/PA

Doug Beattie told BBC News: "The fact it was even considered. The fact it was even talked about is quite bizarre.

"But it tells you what is the mentality. And remember this as well, the same senior civil servant was part of the workstreams for getting government up and running again. The same civil servant is part of the budget negotiations that are going through now. They can all be linked so for us to get confidence in where we are with the civil service it is really important I speak to the head of the civil service."

At the time Mr Sterling wrote: "She [Michelle O'Neill] is clearly frustrated with being a first minister but actually having little power or influence over the health service.

"FM [Arlene Foster] is more circumspect, recognising the 'operational independence' of the health minister.

"Though she too is frustrated at the lack of information coming out of DoH (Department of Health) coupled with frequent surprises eg today's announcement that hospital visits are to end."

It was in response to this email that Mr Widdis, made his reshuffle suggestion, amid a range of different proposals.

He wrote: "There would be more radical options but I presume that they aren't palatable eg: asking Robin to take a different portfolio for the duration (they would have to make a tempting offer) and putting a SF or DUP Minister in?

"Or causing dHondt to be run again."

The Executive Office has been approached for comment.

Mr Widdis also had other less radical suggestions, like developing an emergency programme for government, or creating "an all-Exec overarching Covid strategy" which the first and deputy first ministers "can lead and own".

Mr Swann remained as health minister during the pandemic, and recently returned to the job when devolution was restored earlier this year.

As part of the same exchange of emails between civil servants, Karen Pearson, from the Executive Office, pointed out that ministers were still finding their feet after the recent resumption of devolution.

Among her observations were that "ministers are just back a new ministerial team a real crisis which they can not control and it is scaring them".

In his email at the end of March, Sir David raised another issue.

He said the deputy first minister "revealed what has been increasingly clear with Sinn Fin ministers in recent days is a growing fear of being held corporately responsible, or liable, if things go badly wrong".

He added: "We need to find a way to get them off this hook.

"If it becomes clear that their main priority is to lay out an audit trail and avoid any future blame then everyone else will do the same thing.

"And we'll be paralysed."

The email was sent just after 21:00 on Thursday, 26 March, 2020.

He ended the note saying: "Need to sleep on these two challenges."

Read the original here:

Covid-19 Inquiry: Idea to replace Swann during pandemic 'bizarre' - BBC.com

Remdesivir Shows Reduction in Mortality in Seniors Hospitalized With COVID-19 – Contagionlive.com

April 29, 2024

In a large study, remdesivir (RDV) use was associated with a reduction of mortality in seniors 65 years of age and older who were hospitalized with severe COVID-19 during the period when the Omicron variant was the dominant strain of the virus. The results were shared as late-breaking research at the ongoing ESCMID Global Congress.

Unadjusted mortality rates were 9.9% vs. 13.0% at 14-days and 13.3% vs. 16.9% at 28-days for RDV vs. non-RDV, respectively, the investigators wrote. RDV was associated with a significantly lower 14-day mortality (adjusted hazard ratio [95% CI]: 0.74[0.70-0.79]) and 28-day mortality (0.77[0.73-0.81]) as compared to non-RDV in the overall study cohort.

Jason Okulicz, MD, executive director, Global Medical Affairs, COVID-19 and Emerging Viruses, reiterates the severity and toll of COVID-19 within this patient population.

The elderly populations are a very important population to [consider] for treatment, Okulicz said. In the US in 2023, almost two thirds of patients hospitalized for COVID-19 were over the age 65. And among those who were hospitalized, nearly 90% of deaths that occurred in the hospital due to COVID-19 were in this population.

Study Parameters and Methods Using the PINC AI Healthcare database, the investigators examined patients 65 years of age and older who were hospitalized with a primary diagnosis of COVID-19 between Dec 2021 to April 2023. Their analysis was broken into 3 different groups including: no supplemental oxygen charges (NSOc); low-flow oxygen (LFO); and high-flow oxygen/non-invasive ventilation (HFO/NIV) or invasive mechanical ventilation (IMV)/ECMO, as well as by age groups.

Patients were either in a cohort that included administration of remdesivir in the first 2 days of admission or those not initiating the treatment during their hospitalization, and were matched using 1:1 preferential within-hospital propensity matching (PS) with replacement. They examined the time to 14- and 28-day in-hospital mortality. Okulicz said that over 45,000 patients were given remdesivir to over 20,000, patients who were not given remdesivir.

Oxygen Requirements vs Nonrequirements One of the important findings was that there was a consistent result across baseline supplemental oxygen requirements and different age groups.

"Even among the elderly, with different types of oxygen requirements or nonrequirements, they were shown to have reduced mortality with the use of remdesivir, Okulicz said.

Reference Mozaffari E, et al. Remdesivir reduces mortality in elderly patients 65+ years hospitalised for COVID-19 during Omicron.Late-breaking abstract. Presented at ESCMID. April 27-30, 2024. Barcelona, Spain.

Go here to see the original:

Remdesivir Shows Reduction in Mortality in Seniors Hospitalized With COVID-19 - Contagionlive.com

Stability analysis and numerical evaluations of a COVID-19 model with vaccination – BMC Medical Research … – BMC Medical Research Methodology

April 28, 2024

Let us emphasize that the spectral matrix collocation approach based on the SCPSK may not yield convergence on a long time interval ([t_a,t_b]). One remedy is to use a large number of bases on the long domains accordingly to reach the desired level of accuracy. Another approach is to divide the given interval into a sequence of subintervals and employ the proposed collocation scheme on each subinterval consequently.

Towards this end, we split the time interval ([t_a,t_b]) into (Nge 1) subdomains in the forms

$$begin{aligned} K_n:=[t_{n},t_{n+1}],quad n=0,1,ldots , N-1. end{aligned}$$

Here, we have (t_0:=t_a) and (t_N:=t_b). The uniform time step is taken as (h=t_{n+1}-t_n=(t_b-t_a)/N). Note that by selecting (N=1), we turn back to the traditional spectral collocation method on the whole domain ([t_a,t_b]). Therefore, on each subinterval (K_n) we take the approximate solution of the modelEq. (1) to be in the formEq. (25) as

$$begin{aligned} x^n_{mathcal {J}}(t):=sum limits _{j=0}^{mathcal {J}} omega ^n_j,mathbb {U}_j(t)=varvec{U}_{mathcal {J}}(t),varvec{W}^n_mathcal {J},quad tin K_n, end{aligned}$$

(29)

where we utilized the notations

$$begin{aligned} varvec{W}_{mathcal {J}}^n:=left[ omega ^n_0quad omega ^n_1quad ldots quad omega ^n_{mathcal {J}}right] ^T,quad varvec{U}_{mathcal {J}}(t):=left[ mathbb {U}_0(t)quad mathbb {U}_1(t)quad ldots quad mathbb {U}_J(t)right] , end{aligned}$$

as the vector of unknown coefficients and the vector of SCPSK bases respectively. Once we get the all local approximate solutions for (n=0,1,ldots ,N-1), the global approximate solution on the given (large) interval ([t_a,t_b]) will be constructed in the form

$$begin{aligned} x_{mathcal {J}}(t)=sum limits _{n=0}^{N-1} c_n(t),x^n_{mathcal {J}}(t),quad c_n(t):= left{ begin{array}{ll} 0, &{} tnotin K_n,\ 1, &{} tin K_n.\ end{array}right. end{aligned}$$

In order to collocate a set of ((mathcal {J}+1)) linear equations to be obtained later at some suitable points, we consider the roots of (mathbb {U}_{mathcal {J}+1}(t)) on the subinterval (K_n). By modifying the points giveninEq. (17), we take the collocation nodes as

$$begin{aligned} t_{nu ,n}=frac{1}{2}left( t_n+t_{n+1}+h,cos left( frac{nu ,pi }{mathcal {J}+2}right) right) ,quad nu =1,2,ldots ,mathcal {J}+1. end{aligned}$$

(30)

At the end, we note that in the proposed splitting approach, the given initial conditions of the underlying model problem are prescribed on the first subinterval (K_0). Once the approximate solution on (K_0=[t_0,t_1]) is determined, we utilize it to assign the initial conditions on the next time interval (K_1). To do so, it is sufficient to evaluate the obtained approximation at (t_1). We repeat this idea on the next subintervals in order until we arrive at the last subinterval (K_{N-1}). Below, we illustrate the main steps of our matrix collocation algorithm on an arbitrary subinterval (K_n) for (n=0,1,ldots ,N-1).

Our chief aim is to solve the nonlinear COVID-19 systemEq. (1) efficiently by using the spectral method based on SCPSK basis. Towards this end, we first need to get rid of the nonlinearity of the model. This can be done by employing the Bellmans quasilinearization method (QLM)[39]. Thus we will get more advantages in terms of running time, especially for large values of J in comparison to the performance of directly applied collocation methods to nonlinear models, see cf.[40,41,42]. By combining the idea of QLM and the splitting of the domain we will obtain more gains in terms of accuracy for the approximate solutions of nonlinear modelEq. (1). Let us first describe the technique of QLM. For more information, we may refer the readers to the above-mentioned works.

By reformulating the original COVID-19 modelEq. (1) in a compact form we get

$$begin{aligned} frac{d}{dt} varvec{z}(t)=varvec{G}(t,varvec{z}(t)), end{aligned}$$

(31)

where

$$begin{aligned} varvec{z}(t)=left[ begin{array}{c} S(t)\ S_v(t)\ I(t)\ I_v(t)\ R(t)\ R_v(t)\ J(t)\ J_v(t) end{array}right] ,quad varvec{G}(t,varvec{z}(t))=left[ begin{array}{c} g_1(t)\ g_2(t)\ g_3(t)\ g_4(t)\ g_5(t)\ g_6(t)\ g_7(t)\ g_8(t) end{array}right] = left[ begin{array}{c} Lambda - beta S(I+I_v)- (lambda +mu ) S+ theta _1 R\ -beta ' S_v(I+ I_v)+ theta _2R_v+ lambda S- (delta +mu ) S_v\ beta S(I+ I_v)- (gamma _1+alpha _1+mu ) I \ beta ' S_v(I+ I_v)- (gamma _2+alpha _2+mu )I_v\ gamma _1 I-(theta _1+mu ) R+ eta _1 J \ gamma _2 I_v- (theta _2+mu ) R_v+ eta _2J_v+ delta S_v\ alpha _1 I- (eta _1+mu _1)J\ alpha _2I_v- (eta _2+mu _2) J_v end{array}right] . end{aligned}$$

To begin the QLM process, we assume (varvec{z}_0(t)) is available as an initial rough approximation for the solution (varvec{z}(t)) of the COVID-19 systemEq. (31). Through an iterative manner, the QLM procedure reads as follows

$$begin{aligned} frac{d}{dt}varvec{z}_{s}(t)approx varvec{G}(t,varvec{z}_{s-1}(t))+varvec{G}_{varvec{z}}(t,varvec{z}_{s-1}(t)),left( varvec{z}_{s}(t)-varvec{z}_{s-1}(t)right) ,quad s=1,2,ldots . end{aligned}$$

Here, the notation (varvec{G}_{varvec{z}}) stands for the Jacobian matrix of the COVID-19 systemEq. (31), which is of size 8 by 8. By performing some calculations we reach the linearized equivalent model form as

$$begin{aligned} frac{d}{dt}varvec{z}_{s}(t)+varvec{M}_{s-1}(t),varvec{z}_{s}(t)=varvec{r}_{s-1}(t),qquad s=1,2,ldots , end{aligned}$$

(32)

where (varvec{M}_{s-1}(t):=varvec{J}(S_{s-1}(t), (S_v)_{s-1}(t), I_{s-1}(t), (I_v)_{s-1}(t))) as the Jacobian matrix (varvec{J}) previously constructed inEq. (7). Also we have

$$begin{aligned} varvec{z}_{s}(t)= left[ begin{array}{c} S_{s-1}(t)\ (S_v)_{s-1}(t)\ I_{s-1}(t)\ (I_v)_{s-1}(t)\ R_{s-1}(t)\ (R_v)_{s-1}(t)\ J_{s-1}(t)\ (J_v)_{s-1}(t) end{array}right] ,quad varvec{r}_{s-1}(t)= left[ begin{array}{c} Lambda +beta ,S_{s-1}(t)Big (I_{s-1}(t)+(I_v)_{s-1}(t)Big )\ beta ',(S_v)_{s-1}(t)Big (I_{s-1}(t)+(I_v)_{s-1}(t)Big )\ -beta ,S_{s-1}(t)Big (I_{s-1}(t)+(I_v)_{s-1}(t)Big )\ -beta ',(S_v)_{s-1}(t)Big (I_{s-1}(t)+(I_v)_{s-1}(t)Big )\ 0\ 0\ 0\ 0 end{array}right] . end{aligned}$$

Along with the systemEq. (32) the initial conditions

$$begin{aligned} varvec{z}_{s}(0)=left[ begin{array}{cccccccc} S_0&S_{v0}&I_0&I_{v0}&R_0&R_{v0}&J_0&J_{v0} end{array}right] ^T, end{aligned}$$

(33)

are given due toEq. (2). We now are able to solve the family of linearized initial-value problemsEqs. (32)-(33) numerically by our proposed matrix collocation method on an arbitrary (long) domain ([t_a,t_b]). For this purpose and for clarity of exposition, we restrict our illustrations to a local subinterval (K_n) for (n=0,1,ldots ,N-1).

In view ofEq. (29) by utilizing only ((mathcal {J}+1)) SCPSK basis functions, we assume that the eight solutions of systemEq. (32) can be represented in terms ofEq. (29). Thus, we take these solutions at iteration (sge 1) as

$$begin{aligned} left{ begin{array}{l} S^{n}_{mathcal {J},s}(t)=sum _{j=0}^{mathcal {J}}omega ^{n,s}_{j,1},mathbb {U}_j(t)=varvec{U}_{mathcal {J}}(t),varvec{W}^{n,s}_{mathcal {J},1},quad (S_v)^{n}_{mathcal {J},s}(t)=sum _{j=0}^{mathcal {J}}omega ^{n,s}_{j,2},mathbb {U}_j(t)=varvec{U}_{mathcal {J}}(t),varvec{W}^{n,s}_{mathcal {J},2},\ I^{n}_{mathcal {J},s}(t),=sum _{j=0}^{mathcal {J}}omega ^{n,s}_{j,3},mathbb {U}_j(t)=varvec{U}_{mathcal {J}}(t),varvec{W}^{n,s}_{mathcal {J},3},quad (I_v)^{n}_{mathcal {J},s}(t)~=sum _{j=0}^{mathcal {J}}omega ^{n,s}_{j,4},mathbb {U}_j(t)=varvec{U}_{mathcal {J}}(t),varvec{W}^{n,s}_{mathcal {J},4},\ R^{n}_{mathcal {J},s}(t)=sum _{j=0}^{mathcal {J}}omega ^{n,s}_{j,5},mathbb {U}_j(t)=varvec{U}_{mathcal {J}}(t),varvec{W}^{n,s}_{mathcal {J},5},quad (R_v)^{n}_{mathcal {J},s}(t)=sum _{j=0}^{mathcal {J}}omega ^{n,s}_{j,6},mathbb {U}_j(t)=varvec{U}_{mathcal {J}}(t),varvec{W}^{n,s}_{mathcal {J},6},\ J^{n}_{mathcal {J},s}(t),=sum _{j=0}^{mathcal {J}}omega ^{n,s}_{j,7},mathbb {U}_j(t)=varvec{U}_{J}(t),varvec{W}^{n,s}_{mathcal {J},7},quad (J_v)^{n}_{mathcal {J},s}(t),=sum _{j=0}^{mathcal {J}}omega ^{n,s}_{j,8},mathbb {U}_j(t)=varvec{U}_{mathcal {J}}(t),varvec{W}^{n,s}_{mathcal {J},8},\ end{array}right. end{aligned}$$

(34)

for (tin K_n). Moreover, by (varvec{W}^{n,s}_{mathcal {J},i}= left[ begin{array}{cccc} omega ^{n,s}_{0,i}&omega ^{n,s}_{1,i}&dots&omega ^{n,s}_{mathcal {J},i} end{array}right] ^T) we denote the vectors of unknowns for (1le ile 8) at the iteration (sge 1). Also, the vector of SCPSK basis, i.e., (varvec{U}_mathcal {J}(t)) is defined inEq. (29). We next provide a decomposition for (varvec{U}_mathcal {J}(t)) given by

$$begin{aligned} varvec{U}_mathcal {J}(t)=varvec{Q}_mathcal {J}(t),varvec{F}_mathcal {J}. end{aligned}$$

(35)

Here, the vector (varvec{Q}_mathcal {J}(t)) including the powers of ((t-t_n)) introduced by

$$begin{aligned} varvec{Q}_mathcal {J}(t)=left[ 1quad t-t_nquad (t-t_n)^{2}quad ldots quad (t-t_n)^{mathcal {J}}right] . end{aligned}$$

The next object is the matrix (varvec{F}_mathcal {J}=(f_{i,j})_{i,j=0}^{mathcal {J}}) of size ((mathcal {J}+1)times (mathcal {J}+1)). The entries of the latter matrix are given inEq. (15). One can also show that (det (varvec{F}_mathcal {J})ne 0) and it is a triangular matrix. It follows that

$$begin{aligned} f_{i,j}:= left{ begin{array}{ll} o_{i,j}, &{} textrm{if}~ ile j,\ 0, &{} textrm{if}~ i> j. end{array}right. end{aligned}$$

We then insert the obtained term (varvec{U}_mathcal {J}(t)) inEq. (35) intoEq. (34). The resulting expansions are

$$begin{aligned} left{ begin{array}{l} S^{n}_{mathcal {J},s}(t)=varvec{Q}_mathcal {J}(t),varvec{F}_mathcal {J},varvec{W}^{n,s}_{mathcal {J},1},quad (S_v)^{n}_{mathcal {J},s}(t)=varvec{Q}_mathcal {J}(t),varvec{F}_mathcal {J},varvec{W}^{n,s}_{mathcal {J},2},\ I^{n}_{mathcal {J},s}(t),=varvec{Q}_mathcal {J}(t),varvec{F}_J,varvec{W}^{n,s}_{mathcal {J},3},quad (I_v)^{n}_{mathcal {J},s}(t)~=varvec{Q}_mathcal {J}(t),varvec{F}_mathcal {J},varvec{W}^{n,s}_{mathcal {J},4},\ R^{n}_{mathcal {J},s}(t) =varvec{Q}_mathcal {J}(t),varvec{F}_mathcal {J},varvec{W}^{n,s}_{mathcal {J},5},quad (R_v)^{n}_{mathcal {J},s}(t)=varvec{Q}_mathcal {J}(t),varvec{F}_mathcal {J},varvec{W}^{n,s}_{mathcal {J},6},\ J^{n}_{mathcal {J},s}(t), =varvec{Q}_mathcal {J}(t),varvec{F}_mathcal {J},varvec{W}^{n,s}_{mathcal {J},7},quad (J_v)^{n}_{mathcal {J},s}(t),=varvec{Q}_mathcal {J}(t),varvec{F}_mathcal {J},varvec{W}^{n,s}_{mathcal {J},8}, end{array}right. tin K_n. end{aligned}$$

(36)

We then proceed by nothing that the derivative of the vector (varvec{Q}_mathcal {J}(t)) can be stated in terms of itself. A vivid calculation reveals that

$$begin{aligned} dot{varvec{Q}}_{mathcal {J}}(t)=varvec{Q}_{mathcal {J}}(t),varvec{D}_mathcal {J},quad varvec{D}_mathcal {J}=left[ begin{array}{lllll} 0 &{} 1 &{} 0 &{}ldots &{} 0\ 0 &{} 0 &{} 2 &{}ldots &{} 0\ vdots &{} vdots &{} ddots &{}vdots &{} vdots \ 0 &{} 0 &{} 0 &{}ddots &{} mathcal {J}\ 0 &{} 0 &{} 0 &{} ldots &{} 0 end{array}right] _{(mathcal {J}+1)times (mathcal {J}+1)}. end{aligned}$$

(37)

From this relation, we are able to derive a matrix forms of the derivatives of the unknown solutions inEq. (36).

$$begin{aligned} left{ begin{array}{l} dot{S}^{n}_{mathcal {J},s}(t)=varvec{Q}_mathcal {J}(t),varvec{D}_mathcal {J},varvec{F}_mathcal {J},varvec{W}^{n,s}_{mathcal {J},1},quad (dot{S}_v)^{n}_{mathcal {J},s}(t)=varvec{Q}_mathcal {J}(t),varvec{D}_mathcal {J},varvec{F}_mathcal {J},varvec{W}^{n,s}_{mathcal {J},2},\ dot{I}^{n}_{mathcal {J},s}(t),=varvec{Q}_mathcal {J}(t),varvec{D}_mathcal {J},varvec{F}_mathcal {J},varvec{W}^{n,s}_{mathcal {J},3},quad (dot{I}_v)^{n}_{mathcal {J},s}(t)~=varvec{Q}_mathcal {J}(t),varvec{D}_mathcal {J},varvec{F}_mathcal {J},varvec{W}^{n,s}_{mathcal {J},4},\ dot{R}^{n}_{mathcal {J},s}(t)=varvec{Q}_mathcal {J}(t),varvec{D}_mathcal {J},varvec{F}_mathcal {J},varvec{W}^{n,s}_{mathcal {J},5},quad (dot{R}_v)^{n}_{mathcal {J},s}(t)=varvec{Q}_mathcal {J}(t),varvec{D}_mathcal {J},varvec{F}_mathcal {J},varvec{W}^{n,s}_{mathcal {J},6},\ dot{J}^{n}_{mathcal {J},s}(t),=varvec{Q}_mathcal {J}(t),varvec{D}_mathcal {J},varvec{F}_mathcal {J},varvec{W}^{n,s}_{mathcal {J},7},quad (dot{J}_v)^{n}_{mathcal {J},s}(t),=varvec{Q}_mathcal {J}(t),varvec{D}_mathcal {J},varvec{F}_mathcal {J},varvec{W}^{n,s}_{mathcal {J},8}, end{array}right. tin K_n. end{aligned}$$

(38)

The exact solutions of the linearized systemEq. (32) can be written in a vectorized form as

$$begin{aligned} varvec{z}_s(t)approx varvec{z}^n_{mathcal {J},s}(t):= left[ begin{array}{l} S^{n}_{mathcal {J},s}(t)\ (S_v)^{n}_{mathcal {J},s}(t)\ I^{n}_{mathcal {J},s}(t)\ (I_v)^{n}_{mathcal {J},s}(t)\ R^{n}_{mathcal {J},s}(t)\ (R_v)^{n}_{mathcal {J},s}(t)\ J^{n}_{mathcal {J},s}(t)\ (J_v)^{n}_{mathcal {J},s}(t) end{array}right] ,quad dot{varvec{z}}_s(t)approx frac{d}{dt}varvec{z}^n_{mathcal {J},s}(t):= left[ begin{array}{l} dot{S}^{n}_{mathcal {J},s}(t)\ (dot{S}_v)^{n}_{mathcal {J},s}(t)\ dot{I}^{n}_{mathcal {J},s}(t)\ (dot{I}_v)^{n}_{mathcal {J},s}(t)\ dot{R}^{n}_{mathcal {J},s}(t)\ (dot{R}_v)^{n}_{mathcal {J},s}(t)\ dot{J}^{n}_{mathcal {J},s}(t)\ (dot{J}_v)^{n}_{mathcal {J},s}(t) end{array}right] . end{aligned}$$

(39)

We next introduce the following block diagonal matrices of dimensions (8(mathcal {J}+1)times 8(mathcal {J}+1)) as

$$begin{aligned} widehat{varvec{Q}}(t){} & {} =mathrm {{textbf {Diag}}} left( begin{array}{cccccccc} varvec{Q}_mathcal {J}(t)&varvec{Q}_mathcal {J}(t)&varvec{Q}_mathcal {J}(t)&varvec{Q}_mathcal {J}(t)&varvec{Q}_mathcal {J}(t)&varvec{Q}_mathcal {J}(t)&varvec{Q}_mathcal {J}(t)&varvec{Q}_mathcal {J}(t) end{array}right) ,\ widehat{varvec{D}}{} & {} =mathrm {{textbf {Diag}}} left( begin{array}{cccccccc} varvec{D}_mathcal {J}&varvec{D}_mathcal {J}&varvec{D}_mathcal {J}&varvec{D}_mathcal {J}&varvec{D}_mathcal {J}&varvec{D}_mathcal {J}&varvec{D}_mathcal {J}&varvec{D}_mathcal {J} end{array}right) ,\ widehat{varvec{F}}{} & {} =mathrm {{textbf {Diag}}} left( begin{array}{cccccccc} varvec{F}_mathcal {J}&varvec{F}_mathcal {J}&varvec{F}_mathcal {J}&varvec{F}_mathcal {J}&varvec{F}_mathcal {J}&varvec{F}_mathcal {J}&varvec{F}_mathcal {J}&varvec{F}_mathcal {J} end{array}right) . end{aligned}$$

By the aid of the former definitions, the matrix formats of (varvec{z}^n_{mathcal {J},s}(t)) and (dot{varvec{z}}^n_{mathcal {J},s}(t)) will rewrite concisely as

$$begin{aligned} varvec{z}^n_{mathcal {J},s}(t)=widehat{varvec{Q}}(t),widehat{varvec{F}},varvec{W}^n,quad dot{varvec{z}}^n_{mathcal {J},s}(t)=widehat{varvec{Q}}(t),widehat{varvec{F}},widehat{varvec{D}},varvec{W}^n. end{aligned}$$

(40)

Here, (varvec{W}^n) is the successive vector of eight previously defined vector of unknowns

$$begin{aligned} varvec{W}^n=left[ begin{array}{cccc} varvec{W}^{n,s}_{mathcal {J},1}&varvec{W}^{n,s}_{mathcal {J},2}&ldots&varvec{W}^{n,s}_{mathcal {J},8} end{array}right] ^T. end{aligned}$$

We now can collocate the linearized Eq.(32) at the zeros of SCPSK given inEq. (17) on the subdomain (K_n). We get

$$begin{aligned} frac{d}{dt}varvec{z}_{s}(t_{nu ,n})+varvec{M}_{s-1}(t_{nu ,n}),varvec{z}_{s}(t_{nu ,n})=varvec{r}_{s-1}(t_{nu ,n}),qquad nu =1,2,ldots ,mathcal {J}, end{aligned}$$

(41)

for (s=1,2,ldots). Denote the coefficient matrix by (widehat{varvec{M}}^n_{s-1}) and the right-hand-side vector as (widehat{varvec{R}}^n_{s-1}). These are defined by

$$begin{aligned} widehat{varvec{M}}^n_{s-1}= left[ begin{array}{cccc} varvec{M}_{s-1}(t_{0,n})&{}textbf{0}&{}ldots &{}textbf{0}\ textbf{0}&{}varvec{M}_{s-1}(t_{1,n})&{}ldots &{}textbf{0}\ vdots &{}vdots &{}ddots &{}vdots \ textbf{0}&{}textbf{0}&{}ldots &{}varvec{M}_{s-1}(t_{mathcal {J},n}) end{array}right] ,quad widehat{varvec{R}}^n_{s-1}= left[ begin{array}{c} varvec{r}_{s-1}(t_{0,n})\ varvec{r}_{s-1}(t_{1,n})\ vdots \ varvec{r}_{s-1}(t_{mathcal {J},n}) end{array}right] . end{aligned}$$

Let us define further the vectors of unknowns as

$$begin{aligned} dot{varvec{Z}}^n_s= left[ begin{array}{c} dot{varvec{z}}_{s}(t_{0,n})\ dot{varvec{z}}_{s}(t_{1,n})\ vdots \ dot{varvec{z}}_{s}(t_{mathcal {J},n}) end{array}right] ,quad varvec{Z}^n_s= left[ begin{array}{c} dot{varvec{z}}_{s}(t_{0,n})\ dot{varvec{z}}_{s}(t_{1,n})\ vdots \ dot{varvec{z}}_{s}(t_{mathcal {J},n}) end{array}right] . end{aligned}$$

Consequently, the system of Eq.(41) can be stated briefly as

$$begin{aligned} dot{varvec{Z}}^{n}_{s}+widehat{varvec{M}}^n_{s-1},varvec{Z}^n_s=widehat{varvec{R}}^n_{s-1},quad n=0,1,ldots ,N-1, end{aligned}$$

(42)

and with (s=1,2,ldots). Before we talk about the fundamental matrix equation, we need to state two vectors (varvec{Z}^n_s) and (dot{varvec{Z}}^{n}_{s})inEq. (42) in the matrix representation forms. The proof is easy by just considering the definitions of the involved matrices and vectors inEq. (40).

If two vectors (varvec{z}^n_{mathcal {J},s}(t)) and (dot{varvec{z}}^n_{mathcal {J},s}(t)) inEq. (40) computed at the collocation pointsEq. (30), we arrive at the next matrix forms

$$begin{aligned} varvec{Z}^n_s=bar{widehat{varvec{Q}}},widehat{varvec{F}},varvec{W}^n,qquad dot{varvec{Z}}^n_s=bar{widehat{varvec{Q}}},widehat{varvec{F}},widehat{varvec{D}},varvec{W}^n, end{aligned}$$

(43)

where the matrix (bar{widehat{varvec{Q}}}) is given by

$$begin{aligned} bar{widehat{varvec{Q}}}=[widehat{varvec{Q}}(t_{0,n})quad widehat{varvec{Q}}(t_{1,n})quad ldots quad widehat{varvec{Q}}(t_{mathcal {J},n}) ]^T. end{aligned}$$

Moreover, two matrices (widehat{varvec{Q}}, widehat{varvec{F}}) are defined inEq. (40). Similarly, the vector (varvec{W}^n) is given inEq. (40).

By turning to relationEq. (40) we substitute the derived matrix formats into it. Precisely speaking, after replacing (varvec{Z}^n_s) and (dot{varvec{Z}}^n_s) we gain the so-called fundamental matrix equation (FME) of the form

$$begin{aligned} varvec{B}_n,varvec{W}^n=widehat{varvec{R}}^n_{s-1}, quad textrm{or}quad left[ varvec{B}_n;widehat{varvec{R}}^n_{s-1}right] ,quad sge 1,~0le nle N-1, end{aligned}$$

(44)

where

$$begin{aligned} varvec{B}_n:=bar{widehat{varvec{Q}}},widehat{varvec{F}}+widehat{varvec{M}}^n_{s-1},bar{widehat{varvec{Q}}},widehat{varvec{F}},widehat{varvec{D}}. end{aligned}$$

To complete the process of QLM-SCPSK approach, it is necessary to implement the initial conditionsinEq. (2) and add them intoEq. (44). So, the next task is to constitute the matrix representation ofEq. (2). Let us approach (trightarrow 0) in the first relation ofEq. (40). It gives us

$$begin{aligned} varvec{B}_{0,n},varvec{W}^n=widehat{varvec{R}}^n_{s-1,0},qquad varvec{B}_{0,n}:=widehat{varvec{Q}}(0),widehat{varvec{F}},quad widehat{varvec{R}}^n_{s-1,0}=left[ begin{array}{cccccccc} S_0&S_{v0}&I_0&I_{v0}&R_0&R_{v0}&J_0&J_{v0} end{array}right] ^T. end{aligned}$$

We then replace eight rows of the augmented matrix ([varvec{B}_n;widehat{varvec{R}}^n_{s-1}]) by the already obtained row matrix ([varvec{B}_{0,n};widehat{varvec{R}}^n_{s-1,0}]). Denote the modified FME by

$$begin{aligned} check{varvec{B}_{n}},varvec{W}^n=check{textbf{R}}^n_{s-1},quad textrm{or} quad left[ check{varvec{B}_{n}};check{textbf{R}}^n_{s-1}right] . end{aligned}$$

(45)

This implies that the solution of the modelEq. (1) is obtainable on each subdomain (K_n) by iterating (n=0,1,ldots ,N-1). On (K_0) as the first subdomain, the given initial conditionsinEq. (2) will be used to find the corresponding approximations for the systemEq. (1). Hence, this approximate solutions on (K_0) evaluated at the starting point of (K_1) will be utilized for the initial conditions on (K_1). By repeating this process we acquire all approximations on all (K_n) for (0le nle N-1).

Generally, finding the true solutions of the COVID-19 systemEq. (1) is not possible practically. In this case, the residual error functions (REFs) help us to measure the quality of approximations obtained by the QLM-SCPSK technique. Once we calculate the eight approximations by the illustrated method, we substitute them into the model systemEq. (1). In fact, the REFs are defined as the difference between the left-hand side and the right-hand side of the considered equation. On the subdomain (K_n) we set the REFs as

$$begin{aligned}{} & {} mathbb {R}_{1,mathcal {J}}^{n}(t):=left| dot{S}^{n}_{mathcal {J},s}(t)-Lambda +beta S^{n}_{mathcal {J},s}(t)L^n_{mathcal {J},s}(t)+(lambda +mu ) S^{n}_{mathcal {J},s}(t)- theta _1 R^{n}_{mathcal {J},s}(t)right| cong 0, nonumber \{} & {} mathbb {R}_{2,mathcal {J}}^{n}(t):=left| (dot{S_v})^{n}_{mathcal {J},s}(t)+beta ' (S_v)^{n}_{mathcal {J},s}(t)L^n_{mathcal {J},s}(t)- theta _2(R_v)^{n}_{mathcal {J},s}(t)- lambda S^{n}_{mathcal {J},s}(t)+ (delta +mu ) (S_v)^{n}_{mathcal {J},s}(t)right| cong 0, nonumber \{} & {} mathbb {R}_{3,mathcal {J}}^{n}(t):=left| dot{I}^{n}_{mathcal {J},s}(t)-beta S^{n}_{mathcal {J},s}(t)L^n_{mathcal {J},s}(t)+ (gamma _1+alpha _1+mu ) I^{n}_{mathcal {J},s}(t)right| cong 0, nonumber \{} & {} mathbb {R}_{4,mathcal {J}}^{n}(t):=left| (dot{I_v})^{n}_{mathcal {J},s}(t)- beta ' (S_v)^{n}_{mathcal {J},s}(t)L^n_{mathcal {J},s}(t)+ (gamma _2+alpha _2+mu )(I_v)^{n}_{mathcal {J},s}(t)right| cong 0, nonumber \{} & {} mathbb {R}_{5,mathcal {J}}^{n}(t):=left| dot{R}^{n}_{mathcal {J},s}(t) - gamma _1 I^{n}_{mathcal {J},s}(t)+(theta _1+mu ) R^{n}_{mathcal {J},s}(t)- eta _1 J^{n}_{mathcal {J},s}(t)right| cong 0, nonumber \{} & {} mathbb {R}_{6,mathcal {J}}^{n}(t):=left| (dot{R_v})^{n}_{mathcal {J},s}(t)- gamma _2 (I_v)^{n}_{mathcal {J},s}(t)+ (theta _2+mu ) (R_v)^{n}_{mathcal {J},s}(t)- eta _2(J_v)^{n}_{mathcal {J},s}(t)- delta (S_v)^{n}_{mathcal {J},s}(t)right| cong 0, nonumber \{} & {} mathbb {R}_{7,mathcal {J}}^{n}(t):=left| dot{J}^{n}_{mathcal {J},s}(t) -alpha _1 I^{n}_{mathcal {J},s}(t)+ (eta _1+mu _1)J^{n}_{mathcal {J},s}(t)right| cong 0, nonumber \{} & {} mathbb {R}_{8,mathcal {J}}^{n}(t):=left| (dot{J_v})^{n}_{mathcal {J},s}(t)- alpha _2(I_v)^{n}_{mathcal {J},s}(t) +(eta _2+mu _2) (J_v)^{n}_{mathcal {J},s}(t)right| cong 0, end{aligned}$$

(46)

for a fixed iteration number s and we have defined (L^n_{mathcal {J},s}:=I^{n}_{mathcal {J},s}(t)+ (I_v)^{n}_{mathcal {J},s}(t)) for brevity.

Analogously, at the fixed iteration s, the numerical order of convergence associated with the obtained REFs can be defined in the infinity norm. These are given by

$$begin{aligned} L^{infty }_{ell }equiv L^{infty }_{ell }(mathcal {J}):=max _{0le nle N-1}left( max _{tin K_n},left| mathbb {R}_{ell ,mathcal {J}}^{n}(t)right| right) ,quad ell =1,2,ldots ,8. end{aligned}$$

Therefore, the convergence order (Co) for each solution is defined by

$$begin{aligned} textrm{Co}_{mathcal {J}}^{ell }:=log _2left( frac{L^{infty }_{ell }(mathcal {J})}{L^{infty }_{ell }(2mathcal {J})}right) ,quad ell =1,2,ldots ,8. end{aligned}$$

(47)

View original post here:

Stability analysis and numerical evaluations of a COVID-19 model with vaccination - BMC Medical Research ... - BMC Medical Research Methodology

Can Neosporin in the Nose Help Prevent Viral Infections? – TIME

April 28, 2024

For years, researchers have been working on vaccines that aim to prevent viral infections by strengthening immune defenses at viruses doorway to the body: the nose.

A small study recently published in PNAS presents a similar, if lower-tech, idea. Coating the inside of the nose with the over-the-counter antibiotic ointment Neosporin seems to trigger an immune response that may help the body repel respiratory viruses like those that cause COVID-19 and the flu, the study suggests.

The research raises the idea that Neosporin could serve as an extra layer of protection against respiratory illnesses, on top of existing tools like vaccines and masks, says study co-author Akiko Iwasaki, an immunobiologist at the Yale School of Medicine and one of the U.S. leading nasal vaccine researchers.

The study builds upon some of Iwasakis prior researchwhich has shown that similar antibiotics can trigger potentially protective immune changes in the bodybut its still preliminary, she cautions. For the new study, her team had 12 people apply Neosporin inside their nostrils twice a day for a week, while another seven people used Vaseline for comparison. At several points during the study, the researchers swabbed the participants noses and ran PCR tests to see what was going on inside.

Read More: What to Do About Your Bunions

They found that Neosporinand specifically one of its active ingredients, the antibiotic neomycin sulfateseems to stimulate receptors in the nose that are fooled into thinking theres a viral infection and in turn create a barrier thats put up against any virus, Iwasaki explains. In theory, she says, that means it could protect against a range of different infections.

Right now, though, thats just a theory. For this study, Iwasakis team didnt take the next step of testing whether that immune response actually prevents people from getting infected when theyre exposed to virusesin part because its ethically questionable to intentionally expose people to pathogens for research. (They did, however, demonstrate that rodents whose noses were coated with neomycin were protected from the virus that causes COVID-19.)

On its website, the maker of Neosporin says that the product has not "been tested or formulated to prevent against COVID-19 or any other virus," and also note that they do not advise putting the product inside the eyes, nose, or mouth.

Dr. James Crowe, who directs the Vanderbilt Vaccine Center and was not involved in the research, says the study is intriguing, but hed need to see more human data before he gets excited. Im skeptical it would be strongly effective in people, Crowe says. If you have a modest effect on the virus, is that enough to really benefit you clinically?

It is somewhat counterintuitive to think that an antibiotic, which kills bacteria, could do anything to protect people from viruses. Its not that the antibiotic has a direct effect against viruses, Iwasaki explains. Instead, it seems that neomycin, when applied topically, provoke changes in the body that help it fight off virusesessentially, triggering a natural antiviral effect.

So should you smear Neosporin in your nose next time a COVID-19 wave hits? Not so fast, says Dr. Benjamin Bleier, who specializes in nasal disorders at Massachusetts Eye and Ear and has studied nasal immunity.

Read More: COVID-Cautious Americans Feel Abandoned

Bleier, who was not involved in the new study, calls the research very well done, but says there are questions that need to be answered before it hits clinical prime time. First, could the body develop tolerance or resistance to neomycin if the antibiotic were regularly used in this way? (Antibiotic resistance is a growing concern, and overusing or inappropriately prescribing antibiotics is a contributor to the problem.) Second, could the average person apply neomycin deeply and thoroughly enough for meaningful protection? And finally, could this approach damage the delicate inner nose or have other side effects over time? (Even in the small study, one of the people who used intranasal Neosporin dropped out due to minor side effects, apparently related to a drug allergy.)

Its great science, but theres still a long way to go before we should put it in our noses, agrees Dr. Sean Liu, an infectious disease physician at New Yorks Mount Sinai health system who was also not involved in the study.

Iwasaki agrees that more research is necessary. She says the next step is testing higher doses of neomycin, since Neosporin contains a fairly small amount that may not be enough to provide robust protection for humans. To gather more data, she says, researchers could track people going about their normal livesexcept that some apply neomycin to their noses and some apply Vaselineand see if one group gets sick less often than the other, though that would require a lot of time and people.

Despite the difficulties, Liu says theres good reason for further study. Finding new uses for affordable, widely accessible medications is good for public health, and any progress toward neutralizing viruses is welcome. If the approach is proven to work, it could also be useful to have a tool that's effective against a broad range of viruses and could potentially be paired with other drugs to strengthen its efficacy, Crowe adds.

Plus, Iwasaki says, additional disease-prevention tools could help people who are especially vulnerable to respiratory diseasessuch as those who are immunocompromisedand need additional protection to feel safe. If further research proves promising, Iwasaki says, she could imagine neomycin serving as an additional disease-fighting tool when people are in particularly germy places, like a crowded party or an airport.

Go here to read the rest:

Can Neosporin in the Nose Help Prevent Viral Infections? - TIME

Long COVID: plasma levels of neurofilament light chain in mild COVID-19 patients with neurocognitive symptoms … – Nature.com

April 28, 2024

Graham EL, Clark JR, Orban ZS, Lim PH, Szymanski AL, Taylor C, et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 long haulers. Ann Clin Transl Neurol. 2021;8:107385.

Article CAS PubMed PubMed Central Google Scholar

Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV; WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22:e1027.

Ladds E, Rushforth A, Wieringa S, Taylor S, Rayner C, Husain L, et al. Persistent symptoms after Covid-19: qualitative study of 114 long Covid patients and draft quality principles for services. BMC Health Serv Res. 2020;20(Dec):1144.

Article PubMed PubMed Central Google Scholar

Liotta EM, Batra A, Clark JR, Shlobin NA, Hoffman SC, Orban ZS, et al. Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients. Ann Clin Transl Neurol. 2020;7(Nov):222130.

Article CAS PubMed PubMed Central Google Scholar

Romero-Snchez CM, Daz-Maroto I, Fernndez-Daz E, Snchez-Larsen , Layos-Romero A, Garca-Garca J, et al. Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry. Neurology. 2020;95(Aug):E106070.

PubMed PubMed Central Google Scholar

Koralnik IJ, Tyler KL. COVID-19: a global threat to the nervous system. Vol. 88. Annals of Neurology. John Wiley and Sons Inc.; 2020. p. 111.

Hanson BA, Visvabharathy L, Ali ST, Kang AK, Patel TR, Clark JR. et al. Plasma biomarkers of neuropathogenesis in hospitalized patients with COVID-19 and those with postacute sequelae of SARS-CoV-2 infection. Neurol(R) Neuroimmunol Neuroinflamm. 2022;9:e1151

Article Google Scholar

del Rio C, Collins LF, Malani P. Long-term health consequences of COVID-19. J Am Med Assoc. 2020;324:17234.

Article Google Scholar

Butler M, Pollak TA, Rooney AG, Michael BD, Nicholson TR. Neuropsychiatric complications of covid-19. Vol. 371, The BMJ. BMJ Publishing Group; 2020.

Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(May):41627.

Article PubMed PubMed Central Google Scholar

Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(Jan):22032.

Article CAS PubMed PubMed Central Google Scholar

Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18(Sep):e1003773.

Article CAS PubMed PubMed Central Google Scholar

Solomon T. Neurological infection with SARS-CoV-2the story so far. Vol. 17. Nature Reviews Neurology. Nature Research; 2021. p. 656.

Theoharides TC. Could SARS-CoV-2 spike protein be responsible for long-COVID syndrome? Vol. 59. Molecular Neurobiology. Springer; 2022. p. 185061.

The Lancet. Facing up to long COVID. Vol. 396, The Lancet. Lancet Publishing Group; 2020. p. 1861.

Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Vol. 14. Nature Reviews Neurology. Nature Publishing Group; 2018. p. 57789.

Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. Journal of Neurology, Neurosurgery and Psychiatry. BMJ Publishing Group; 2019.

Hendricks R, Baker D, Brumm J, Davancaze T, Harp C, Herman A, et al. Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and blood. Bioanalysis. 2019;11:140518.

Article CAS PubMed Google Scholar

Delcoigne B, Manouchehrinia A, Barro C, Benkert P, Michalak Z, Kappos L, et al. Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology. 2020;94:e120112.

Article CAS PubMed PubMed Central Google Scholar

Moscoso A, Grothe MJ, Ashton NJ, Karikari TK, Lantero Rodrguez J, Snellman A, et al. Longitudinal associations of blood phosphorylated Tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease. JAMA Neurol. 2021;78:396406.

Article PubMed Google Scholar

Fisse AL, Pitarokoili K, Leppert D, Motte J, Pedreiturria X, Kappos L, et al. Serum neurofilament light chain as outcome marker for intensive care unit patients. J Neurol. 2021;268:13239.

Article CAS PubMed Google Scholar

Moseby-Knappe M, Mattsson N, Nielsen N, Zetterberg H, Blennow K, Dankiewicz J, et al. Serum neurofilament light chain for prognosis of outcome after cardiac arrest. JAMA Neurol. 2019;76(Jan):6471.

Article PubMed Google Scholar

Cooper J, Stukas S, Hoiland RL, Fergusson NA, Thiara S, Foster D, et al. Quantification of neurological blood-based biomarkers in critically Ill patients with coronavirus disease 2019. Crit Care Explor. 2020;2(Oct):e0238.

Article PubMed PubMed Central Google Scholar

Ameres M, Brandstetter S, Toncheva AA, Kabesch M, Leppert D, Kuhle J, et al. Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19. Vol. 267, Journal of Neurology. Springer Science and Business Media Deutschland GmbH; 2020. p. 34768.

Hay M, Ryan L, Huentelman M, Konhilas J, Hoyer-Kimura C, G Beach T, et al. Serum neurofilament light is elevated in COVID-19 positive adults in the ICU and is associated with co-morbid cardiovascular disease, neurological complications, and acuity of illness. Cardiol Cardiovasc Med. 2021;05:55165.

Article Google Scholar

Saller T, Petzold A, Zetterberg H, Kuhle J, Chappell D, von Dossow V, et al. A case series on the value of tau and neurofilament protein levels to predict and detect delirium in cardiac surgery patients. Biomed Pap. 2019;163:2416.

Article Google Scholar

Marchegiani F, Recchioni R, Marcheselli F, di Rosa M, Sabbatinelli J, Matacchione G, et al. Association of admission serum levels of neurofilament light chain and in-hospital mortality in geriatric patients with COVID-19. Journal of Neurology. Springer Science and Business Media Deutschland GmbH; 2022.

De Lorenzo R, Lor NI, Finardi A, Mandelli A, Cirillo DM, Tresoldi C, et al. Blood neurofilament light chain and total tau levels at admission predict death in COVID-19 patients. J Neurol. 2021;268:443642.

Article PubMed PubMed Central Google Scholar

Prudencio M, Erben Y, Marquez CP, Jansen-West KR, Franco-Mesa C, Heckman MG, et al. Serum neurofilament light protein correlates with unfavorable clinical outcomes in hospitalized patients with COVID-19. Sci Transl Med 2021;13:eabi7643.

Article CAS PubMed PubMed Central Google Scholar

Masvekar RR, Kosa P, Jin K, Dobbs K, Stack MA, Castagnoli R, et al. Prognostic value of serum/plasma neurofilament light chain for COVID-19-associated mortality. Ann Clin Transl Neurol. 2022;9:62232.

Article CAS PubMed PubMed Central Google Scholar

Aamodt AH, Hgestl EA, Popperud TH, Holter JC, Dyrhol-Riise AM, Tonby K, et al. Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19. J Neurol. 2021;268:357483.

Article CAS PubMed PubMed Central Google Scholar

Kwok KO, Huang Y, Tsoi MTF, Tang A, Wong SYS, Wei WI, et al. Epidemiology, clinical spectrum, viral kinetics and impact of COVID-19 in the Asia-Pacific region. Respirology. 2021;26:32233.

Fontes-Dantas FL, Fernandes GG, Gutman EG, De Lima EV, Antonio LS, Hammerle MB, et al. SARS-CoV-2 spike protein induces TLR4-mediated long-term cognitive dysfunction recapitulating post-COVID syndrome in mice. Cell Rep. 2023;42:112189 https://linkinghub.elsevier.com/retrieve/pii/S2211124723002000.

Article CAS PubMed PubMed Central Google Scholar

Smith A. Symbol digit modalities test (SDMT). Manual (Revised). Los Angeles: Western Psychological Services; 1982.

Gimnez-Garz C, Garcs JJ, Urios A, Mangas-Losada A, Garca-Garca R, Gonzlez-Lpez O, et al. The PHES battery does not detect all cirrhotic patients with early neurological deficits, which are different in different patients. PLoS ONE. 2017;12:e0171211.

Article PubMed PubMed Central Google Scholar

Sheridan LK, Fitzgerald HE, Adams KM, Nigg JT, Martel MM, Puttler LI, et al. Normative symbol digit modalities test performance in a community-based sample. Arch Clin Neuropsychol. 2006;21:238.

Article PubMed Google Scholar

Parmenter BA, Testa SM, Schretlen DJ, Weinstock-Guttman B, Benedict RHB. The utility of regression-based norms in interpreting the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc. 2010;16:616.

Article PubMed Google Scholar

Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:11213.

Mazza MG, Palladini M, Villa G, de Lorenzo R, Rovere Querini P, Benedetti F. Prevalence, trajectory over time, and risk factor of post-COVID-19 fatigue. J Psychiatr Res. 2022;155:1129.

Article PubMed PubMed Central Google Scholar

Grover S, Sahoo S, Mishra E, Gill KS, Mehra A, Nehra R, et al. Fatigue, perceived stigma, self-reported cognitive deficits and psychological morbidity in patients recovered from COVID-19 infection. Asian J Psychiatr. 2021;64:102815.

Article PubMed PubMed Central Google Scholar

Sarda R, Kumar A, Chandra A, Bir M, Kumar S, Soneja M, et al. Prevalence of Long COVID-19 and its Impact on Quality of Life Among Outpatients With Mild COVID-19 Disease at Tertiary Care Center in North India. J Patient Exp. 2022;9;17.

Cristillo V, Pilotto A, Piccinelli SC, Gipponi S, Leonardi M, Bezzi M, et al. Predictors of brain fog 1 year after COVID-19 disease. Neurol Sci. 2022;43:57957.

Article PubMed PubMed Central Google Scholar

Krishnan K, Miller AK, Reiter K, Bonner-Jackson A. Neurocognitive profiles in patients with persisting cognitive symptoms associated with COVID-19. Arch Clin Neuropsychol. 2022;37:72937.

Article PubMed Google Scholar

Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:36170.

Fernndez-de-las-Peas C, Rodrguez-Jimnez J, Palacios-Cea M, de-la-Llave-Rincn AI, Fuensalida-Novo S, Florencio LL, et al. Psychometric properties of the hospital anxiety and depression scale (HADS) in previously hospitalized COVID-19 patients. Int J Environ Res Public Health. 2022;19:9273.

Article PubMed PubMed Central Google Scholar

Bjelland I, Dahl AA, Haug T, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale: an updated literature review. J Psychosom Res. 2002;52:6977.

Shanbehzadeh S, Tavahomi M, Zanjari N, Ebrahimi-Takamjani I, Amiri-Arimi S. Physical and mental health complications post-COVID-19: scoping review. Vol. 147. Journal of Psychosomatic Research. Elsevier Inc.; 2021.

Liu C, Pan W, Li L, Li B, Ren Y, Ma X. Prevalence of depression, anxiety, and insomnia symptoms among patients with COVID-19: a meta-analysis of quality effects model. Vol. 147. Journal of Psychosomatic Research. Elsevier Inc.; 2021.

Olssn I, Mykletun A, Dahl AA. The hospital anxiety and depression rating scale: a cross-sectional study of psychometrics and case finding abilities in general practice. BMC Psychiatry. 2005;5:46.

Article PubMed PubMed Central Google Scholar

Jacobs MM, Evans E, Ellis C. Racial, ethnic, and sex disparities in the incidence and cognitive symptomology of long COVID-19. J Natl Med Assoc. 2023;115:23343.

PubMed Google Scholar

Sylvester SV, Rusu R, Chan B, Bellows M, OKeefe C, Nicholson S. Sex differences in sequelae from COVID-19 infection and in long COVID syndrome: a review. Curr Med Res Opin. 2022;38:13919.

Article CAS PubMed Google Scholar

Bai F, Tomasoni D, Falcinella C, Barbanotti D, Castoldi R, Mul G, et al. Female gender is associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect. 2022;28:611.e9611.e16.

Article CAS PubMed Google Scholar

Sharma G, Volgman AS, Michos ED. Sex differences in mortality from COVID-19 pandemic. JACC Case Rep. 2020;2:140710.

Article PubMed PubMed Central Google Scholar

Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:62638.

Article CAS PubMed Google Scholar

Kopel J, Perisetti A, Roghani A, Aziz M, Gajendran M, Goyal H. Racial and gender-based differences in COVID-19. Front Public Health. 2020;8:418.

Article PubMed PubMed Central Google Scholar

Klein SL. Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases. BioEssays. 2012;34:10509.

Article CAS PubMed PubMed Central Google Scholar

Frontera JA, Sabadia S, Yang D, de Havenon A, Yaghi S, Lewis A, et al. Life stressors significantly impact long-term outcomes and post-acute symptoms 12-months after COVID-19 hospitalization. J Neurol Sci. 2022;443:120487.

Article PubMed PubMed Central Google Scholar

Zeng F, Dai C, Cai P, Wang J, Xu L, Li J, et al. A comparison study of SARSCoV2 IgG antibody between male and female COVID19 patients: a possible reason underlying different outcome between sex. J Med Virol. 2020;92:20504.

Article CAS PubMed PubMed Central Google Scholar

Stewart S, Newson L, Briggs TA, Grammatopoulos D, Young L, Gill P. Long COVID riska signal to address sex hormones and womens health. Lancet Reg Health. 2021;11:100242.

Google Scholar

See the original post:

Long COVID: plasma levels of neurofilament light chain in mild COVID-19 patients with neurocognitive symptoms ... - Nature.com

Did California’s pediatric COVID-19 vaccination program reduce reported cases and hospitalizations? – News-Medical.Net

April 28, 2024

In a recent study published in the journal JAMA Network Open, researchers investigated whether the coronavirus disease 2019 (COVID-19) vaccine for adolescents between the ages of 12 and 15 years, which was approved in May 2021, was associated with changes in the incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and related hospitalizations among the pediatric population in California, United States (U.S.).

Study:COVID-19 Vaccination and Incidence of Pediatric SARS-CoV-2 Infection and Hospitalization. Image Credit:Prostock-studio/Shutterstock.com

The spread and severity of the COVID-19 pandemic have been successfully controlled due to the rapid development of vaccines against SARS-CoV-2 and concerted efforts worldwide to vaccinate adult and at-risk populations.

The messenger ribonucleic acid (mRNA) vaccines against SARS-CoV-2, developed largely by Moderna and Pfizer BioNTech, were widely used for the adult populations.

Since children and adolescents were not found to be at a high risk of severe COVID-19, developing vaccines for the younger populations was of secondary priority during the peak periods of the pandemic.

However, in May 2021, the first mRNA COVID-19 vaccine for adolescents between 12 and 15 years was approved. In the subsequent months, vaccines for children between the ages of five and 11 years and six months and five years were also approved.

Although these vaccines are safe, vaccine hesitancy because of parental concerns about safety and adverse effects, and perceptions of reduced severity of the infection among children have resulted in low vaccine uptake among the younger populations.

In the present study, the researchers examined whether the COVID-19 vaccine for adolescents impacted the incidence of SARS-CoV-2 infection and hospitalizations among the pediatric population in California.

A better understanding of the impact of the vaccine in lowering incidence rates, reducing the severity of the disease, and mitigating the need for hospitalization is essential in formulating future public health policies on booster doses and developing vaccines against emerging SARS-CoV-2 variants.

The researchers analyzed deidentified data for close to four million pediatric COVID-19 cases and over 12,000 hospitalizations from California.

The outcomes associated with COVID-19 vaccination, including the incidence of SARS-CoV-2 infections and hospitalizations, were analyzed for each county and state according to the vaccine introduction phases for the three age groups.

The deidentified data contained age, county of residence, and hospitalization status information. A polymerase chain reaction (PCR) test was required to confirm COVID-19.

For the statistical analyses, the researchers grouped the cases based on county of residence, as well as age groups according to vaccine eligibility.

Furthermore, the data for each age group was also divided into periods of vaccine ineligibility and eligibility, and the outcomes were evaluated from a month after the vaccination until the analysis of the data or the beginning of the vaccine eligibility period for the next age group.

The results suggested that the COVID-19 vaccine effectively limited the transmission of SARS-CoV-2 among the pediatric population in California.

The analysis found that close to 380,000 COVID-19 cases and 273 hospitalizations among children between the ages of six months and 15 years were averted in four to seven months after the availability of the vaccine. These numbers represent 26% of the cases in the pediatric population.

The researchers stated that their results among the pediatric population were similar to those from various U.S. and Israeli studies reporting the effectiveness of the COVID-19 vaccine in averting a substantial number of COVID-19 cases among the adult population.

The positive impact of the COVID-19 vaccine was found to be the highest among children between the ages of 12 and 15 years.

Among children ages six months to five years, the reduction in the number of COVID-19 cases was not found to be significant. However, the researchers believe this could be because of low transmission rates of the variant circulating during the evaluation period for that age group.

Notably, despite the vaccination coverage being just above half (53.5%) among adolescents between the ages of 12 and 15 years and even lower among children below 12, a total of 376,085 cases of COVID-19 were averted in California.

These findings highlight the effectiveness of the COVID-19 vaccine in lowering the incidence and severity of SARS-CoV-2 infections and limiting the transmission of the virus among children and adolescents.

To conclude, the study found that despite just over 50% vaccination coverage, the COVID-19 mRNA vaccine approved for use among adolescents and children in the U.S. averted close to 400,000 cases among the pediatric population.

These results highlighted the importance of the COVID-19 vaccine in protecting individuals of all age groups against SARS-CoV-2 infections. Furthermore, these findings also support future public health decisions to administer booster doses.

Journal reference:

Head, J. R., Collender, P. A., Len, Toms M, White, L. A., Sud, S. R., Camponuri, S. K., Lee, V., Lewnard, J. A., & Remais, J. V. (2024). COVID-19 Vaccination and Incidence of Pediatric SARS-CoV-2 Infection and Hospitalization. JAMA Network Open. doi:https://doi.org/10.1001/jamanetworkopen.2024.7822. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2817868

See the article here:

Did California's pediatric COVID-19 vaccination program reduce reported cases and hospitalizations? - News-Medical.Net

Page 4«..3456..1020..»